Skip to main content
Premium Trial:

Request an Annual Quote

Axon Signs Resale, Licensing Agreements with Affymetrix

NEW YORK, April 13 (GenomeWeb News) - Axon Instruments will supply Affymetrix with scanners for resale and has licensed scanning technology for spotted arrays from Affymetrix, the company said today.

 

Under the multi-year private-label resale agreement, Axon will provide customized versions of its ImageXpress 5000A automated cellular imaging and analysis scanner to Affymetrix, which include hardware and software jointly developed by the two companies. Affymetrix will purchase a certain minimum number of the scanners and software from Axon and sell them as part of its new high-throughput GeneChip HTA system.

 

Further, Union City, Calif.-based Axon has licensed technology from Affymetrix covering the manufacture and sale of scanners and software for spotted microarrays, but not for Affymetrix's photolithographic microarray format.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.